期刊文献+

非小细胞肺癌患者K-ras的表达及其与预后的关系 被引量:1

下载PDF
导出
摘要 目的探讨非小细胞肺癌(NSCLC)中K-ras的表达及与预后的关系。方法采用免疫组化方法检测160例病理证实的NSCLC组织中K-ras的表达,并根据结果分为K-ras(+)组和K-ras(-)组,调查根治术后影响患者预后的因素。结果 NSCLC组织K-ras阳性表达率为61.2%,明显高于正常肺组织(P<0.05);K-ras表达与组织学类型、吸烟史及淋巴结转移有关。108例术后单纯化疗患者中,K-ras(-)组生存期长于K-ras(+)组(P<0.05)。结论 K-ras蛋白的表达与NSCLC的发生、发展及预后相关。
出处 《山东医药》 CAS 北大核心 2010年第32期40-41,共2页 Shandong Medical Journal
基金 河南省科技攻关项目(82300450240)
  • 相关文献

参考文献6

  • 1Guo W, Wu S, Liu J, et al. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota [ J ]. Cancer Res, 2008,68 ( 18 ) :7403-7408.
  • 2Cvetkovic G, Plavec G, Tomie I, et al. K-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer [ J]. Vojnosanit Pregl, 2009,66 ( 2 ) : 149-155.
  • 3Loriot Y, Mordant P, Deutsch E, et al. Are RAS mutations predictive markers of resistance to standard chemotherapy [ J]. Nat Rev Clin Oncol, 2009,6(9) :528-534.
  • 4Kefeli U, Kaya S, Ustaalioglu BO, et al. Prognostic factors in elderly patients with non-small cell lung cancer: a two-center experience [ J]. Med Oncol, 2010 [ Epub ahead of print].
  • 5Wheatley-Price P, Le Maitre A, Ding K, et al. The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non- small cell lung cancer chemotherapy trials [ J ]. J Thorac Oncol, 2010,5 (5) :640-648.
  • 6Fisseler-Eekhoff A. Prognostic factors in histopathology of lung cancer [J]. Front Radiat Ther Oncol, 2010,42:1-14.

同被引文献29

  • 1孙光远,赵学维,李兵,徐志飞,何金,刘惠敏.EGFR在女性非小细胞肺癌中的表达及临床意义[J].中国癌症杂志,2007,17(5):380-384. 被引量:10
  • 2Guo W, Wu S, Liu J, et al. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota [J]. CancerRes, 2008,68(18):7403-7408.
  • 3Miller V A,Riely G J,Zakowski M F,etal. Molecular charac- teristics of bronchioloalveolar carcinoma and adenocarcinoma, bronehioloalveolar carcinoma subtype, predict response to er- lotinib[J]. Chin Chicol, 2008,26(9) : 1472-1478.
  • 4Linardou H, Dahabreh I J, Kanaloupiti D, et al. Assessment of K-RAS mutations as a mechanism associated with resistance to EGFR targeted agents: a systematic review and meta-analysis of studies in advanced non-small cell lung cancer and metastatic colorectal cancer[J]. The Lancet Oncology, 2008, 9 (10) : 962-972.
  • 5Sreeja L, Syamala V, Raveendran P B, et al. P53 Arg72Pro polymorphism predicts survival outcome in lung cancer pa- tients in indian population[J]. Cancer Investigation, 2008,26 (1) :41-46.
  • 6Scagliotti G V,Selvaggi G,Novello S,etal. The biology of epi- dermal growth factor receptor in lung cancer[J]. Clin Cancer Res, 2004,10 : 4227-4232.
  • 7Selvaggi G, Novello S, Torri V,et al. Epidermal growth factor over expression correlates with a poor prognosis in cornp lately resected non small cell lung cancer[J]. Ann oncol, 2004, 15 (1) :28.
  • 8Xanthoulea S,Pasparakis M,Kousteni S,et al. Tumor necro- sis factor (TNF) receptor shedding controls thresholds of in- nate immune activation that balance opposing TNF functions in infectious and inflammatory diseases [J]. J Exp Med, 2004,200 : 367-376.
  • 9Baresehino M A,Scheino C,Rossi A,et al. Treatment of ad- vanced non-small cell lung cancer[J]. J Orac Dis, 2011,3 (2) :122-133.
  • 10Brabender J, Danenberg K D, Metzger R, et al. Epidermal growth factor receptor and HER-2/neu mRNA expression in non-small cell lung cancer is correlated with survival[J]. Clin Cancer Res, 2001,7 : 1850-1855.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部